Dr. Falutz is Assistant Professor of Medicine at McGill University, and a Senior Physician in the Division of Geriatrics at the McGill University Health Center. He attended McGill University School of Medicine and completed his residency in general internal medicine with subspecialty training in internal medicine and geriatrics. He has been actively involved in both the clinical care of HIV-infected persons and in clinical research related to HIV disease since the 1980’s. He was on sabbatical at the UCLA HIV CARE Clinic from 1991-2.
Dr. Falutz is past Director of the HIV Metabolic Clinic at the Immune Deficiency Treatment Center of the Montreal General Hospital. He is currently Director of the Comprehensive HIV and Aging Initiative of the Chronic Viral Illness Service at the McGill University Hospital Center.
Dr. Falutz has initiated and participated in numerous HIV-related clinical studies. His research focus has been on the interaction of metabolic complications, HIV/HAART-related body composition changes and HIV disease. He is a leader in developing interdisciplinary HIV teaching programs for health sciences students, and is active in educational programs about HIV disease. He is involved in a leading capacity in the assessment and management of frailty in patients aging with HIV. He was a co-principal investigator in studies of a novel recombinant human growth hormone releasing factor, tesamorelin, as treatment for HIV/HAART associated visceral adiposity. This drug is now licensed in Canada and the US. He is an investigator and coordinator for the Canadian involvement in the international REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) Study.